Research article · 10 Apr 2025
Conference abstractPublished 26 Aug 2013
Ampi-109, a novel Vitamin D analog for androgen-insensitive prostate and renal cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Non-classical properties of 1α, 25-dihydroxyvitamin D3 (1, 25(OH) 2D3 ), the vitamin D hormone includes inhibition of proliferation and differentiation of malignant cells raising its potential as a cancer therapeutic agent. But, therapeutic use of 1, 25(OH) 2D3 in various cancers has been limited by the risk of toxicity related to hypercalcemia and hypercalciuria at clinically useful doses, thereby setting the ground for developing 1, 25(OH) 2D3 -analogs with low toxicity and potent anti-proliferative activity. Our laboratory has developed AMPI-109, a novel alkylating analog of 1, 25(OH) 2D3 . We observed that AMPI-109 is a significantly stronger anti-proliferative agent than 1, 25(OH) 2D3 in several prostate and renal cancer cells. But, AMPI-109 did not inhibit the growth of normal prostate and renal cells. We noted that AMPI-109 is a significantly superior inhibitor of renal cancer cell growth than afinitor, axitinib, sorafenib and sunitinib, the currently approved drugs for renal cell carcinoma. Most significantly, AMPI-109 strongly inhibited tumor-growth in mouse models of human androgen-insensitive prostate and renal cancers, demonstrating the potential of AMPI-109 as a therapeutic agent in these malignancies. AMPI-109 was initially developed as an affinity alkylating agent for nuclear vitamin D receptor, the transcriptional factor responsible for the cellular actions of 1,25(OH) 2D3 . But, our recent studies demonstrate that the anti-proliferative action of AMPI-109 is independent of VDR in prostate and kidney cancer cells, setting AMPI-109 apart from all known analogs of 1,25(OH) 2D3 . In this presentation we will delineate these results and discuss the potential of AMPI-109 as an effective and safe therapeutic agent for androgen-insensitive prostate and renal cancers.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Endocrinology & Metabolic Syndrome.
Perspective · 22 Jan 2025
Stem Cells of Endocrine Organs in Normal Physiology and Disease
Perspective · 20 Jan 2025
An In-Depth Overview of Reproductive Endocrinology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalEndocrinology & Metabolic Syndrome
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Rahul Ray”
